Science Daily - Heart Disease

SEPTEMBER 23, 2024

With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.

Medicare 130

Medicare Obesity Cardiovascular Disease Diabetes 130

Med Page Today

MARCH 21, 2024

(MedPage Today) -- Medicare will cover the weight-loss drug semaglutide (Wegovy) under its Part D drug program for patients with overweight or obesity who have preexisting heart disease and need the drug to prevent heart attacks or strokes, the.

Medicare 132

Medicare Heart attacks Heart Attack Obesity 132

CardiacWire

MARCH 24, 2024

Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.

Medicare 59

Medicare Obesity CMS Medicaid 59

Science Daily - Heart Disease

AUGUST 26, 2024

million Medicare beneficiaries are most likely to become eligible for semaglutide. If Medicare Part D narrowly defines cardiovascular disease, majority of patients would remain ineligible while new federal spending could still exceed $10 billion. A new study estimates that 3.6

Medicare 55

Medicare Obesity Cardiovascular Disease 55

Journal of the American Heart Association

JANUARY 10, 2025

Many patients with NVAF are obese and manage other health conditions requiring multiple medications. Cohorts were balanced for demographic and baseline characteristics using propensity score matching.

Atrial Fibrillation 40

Atrial Fibrillation Obesity Medicare Hospital 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:The paucity of large-scale data exploring the effect of prior bariatric surgery on recurrent stroke outcomes in elderly obese stroke survivors led us to address the gap, with an emphasis on the risk of recurrent stroke and its trends.Methods:A retrospective study was conducted using National Inpatient Sample data from 2016-2019.

Obesity 40

Obesity Inpatient Strokes Stroke 40

Circulation: Heart Failure

JANUARY 26, 2024

CONCLUSIONS:Bariatric surgery and pharmacotherapies with weight loss effects are associated with a lower risk of adverse outcomes among older patients with HF and obesity; however, overall utilization remains low. In propensity-matched analysis over a median follow-up of 2.8 0.99];P=0.04).CONCLUSIONS:Bariatric

Heart Failure 40

Heart Failure Obesity Outcomes Medicare 40